S1PR modulators linked to seizure risk in MS trial meta-analysis
Researchers reviewed 63 trials with 53,535 patients, 120 of whom had seizures
People with multiple sclerosis (MS) have a twofold higher risk of seizures compared with the general population, according to pooled data from clinical trials.
Among MS patients, treatment with sphingosine-1-phosphate receptor (S1PR) modulators, a class of MS disease-modifying therapies (DMTs) that includes the oral medications Gilenya (fingolimod), Mayzent (siponimod), Ponvory (ponesimod), and Zeposia (ozanimod), significantly increased the risk of seizures compared with other treatments.
“Epilepsy represents a significant comorbidity [co-existing condition] in the context of MS, warranting intensified efforts to uncover its underlying triggers and enhance strategies for both prevention and treatment,” the researchers wrote in “Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials,” which was published in the Journal of Neurology, Neurosurgery & Psychiatry.
Complete article:
https://multiplesclerosisnewstoday.c...alysis/
Researchers reviewed 63 trials with 53,535 patients, 120 of whom had seizures
People with multiple sclerosis (MS) have a twofold higher risk of seizures compared with the general population, according to pooled data from clinical trials.
Among MS patients, treatment with sphingosine-1-phosphate receptor (S1PR) modulators, a class of MS disease-modifying therapies (DMTs) that includes the oral medications Gilenya (fingolimod), Mayzent (siponimod), Ponvory (ponesimod), and Zeposia (ozanimod), significantly increased the risk of seizures compared with other treatments.
“Epilepsy represents a significant comorbidity [co-existing condition] in the context of MS, warranting intensified efforts to uncover its underlying triggers and enhance strategies for both prevention and treatment,” the researchers wrote in “Incidence and determinants of seizures in multiple sclerosis: a meta-analysis of randomised clinical trials,” which was published in the Journal of Neurology, Neurosurgery & Psychiatry.
Complete article:
https://multiplesclerosisnewstoday.c...alysis/